Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
about
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancerAdvances in immunotherapy for treatment of lung cancerEndocrinopathies in survivors of childhood neoplasiaMolecular and Cellular Characterization of Human CD8 T Suppressor CellsAcute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer.Molecular mimicry and clonal deletion: A fresh look.Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.A Century of Radiation Therapy and Adaptive ImmunityPharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab.Programmed death-1 & its ligands: promising targets for cancer immunotherapy.A perspective on the impact of radiation therapy on the immune rheostat.Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancerHow to train your oncolytic virus: the immunological sequel.Ipilimumab in patients with melanoma and autoimmune diseaseImmune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review.Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis.Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus.Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.Immune-Related Thyroiditis with Immune Checkpoint InhibitorsA Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor ImmunityClinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
P2860
Q26769713-E4245541-C989-4539-862C-66973943CF34Q26778790-6A4A0F94-A31E-4A3F-98B5-A0E7020EA8ECQ27009171-57A71CB9-0C40-477B-9F33-D2C20F09B5EBQ28066113-3D7FDC00-DBF2-4537-9655-490D88254150Q30641952-C6E89D96-BCB5-4BE3-9A9D-5209A1F94360Q31034415-E71E1010-A859-4315-B3FF-4BCF55E1712CQ33764931-975A3B87-9052-4670-B3F0-1D7A7FD85AC3Q34436005-97554088-5CFD-4CE4-9576-A19AB1405DF2Q36165605-92B743D1-0630-486D-8109-4326273A0758Q37518341-0DE733BA-9553-4FAB-9554-0E79A592C87DQ37747153-CF0A4C5F-4668-40FB-9E7E-98D52767AAAFQ38267175-0CCA7B2F-F02E-4C26-800D-0E025D14D67EQ38447992-3F9B73C2-C3EE-487F-B1FD-1CC798703757Q38490909-BEF835F0-DC0B-4F59-B5F6-FCE290921C81Q38562062-84A5BDDC-5785-4C50-9749-F58A8417AB46Q38679488-5C27ACC4-4F09-4AD2-9771-909890DB6432Q39085984-93230702-6F93-4DB2-8029-4C32F4CE3239Q39270453-BB7499A0-C2CC-4DE1-BB6C-4B610D198942Q40611325-A5E638B9-3E96-4802-BE6F-6384ABE25F04Q41991133-9939CDAE-0BCC-4571-AC4A-E360FA1FBE71Q46694815-CDF499AA-6563-485E-B47E-365039A74334Q48102914-B2919946-2192-4957-9A8E-482BA1A165E4Q48354790-489E662F-B15E-488F-8047-2493392C2ACDQ49166546-38F289DA-9FE1-4A28-A8FF-6D206FB16A53Q49315568-8EB8C66F-04A2-480B-9AD9-311B055A8730Q51133960-37098322-B98B-4073-B5D2-E501098CB2B6Q51627654-62298E31-2422-478D-9EB7-36C65E9F6B72Q52615452-77C73AEE-BE05-4E4D-8AB2-4B8E0AE2FF19Q57146198-B8122B48-AB1D-42F8-B6DE-C5E95BA34FD4Q57300170-BEDB93AE-0F96-4625-A961-DB2184805872Q58750630-8433ABE1-D2AA-4FFC-A912-1033549C0ADE
P2860
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Opportunistic Autoimmune Disor ...... tors Anti-CTLA-4 and Anti-PD-1
@ast
Opportunistic Autoimmune Disor ...... tors Anti-CTLA-4 and Anti-PD-1
@en
type
label
Opportunistic Autoimmune Disor ...... tors Anti-CTLA-4 and Anti-PD-1
@ast
Opportunistic Autoimmune Disor ...... tors Anti-CTLA-4 and Anti-PD-1
@en
prefLabel
Opportunistic Autoimmune Disor ...... tors Anti-CTLA-4 and Anti-PD-1
@ast
Opportunistic Autoimmune Disor ...... tors Anti-CTLA-4 and Anti-PD-1
@en
P2860
P356
P1476
Opportunistic Autoimmune Disor ...... tors Anti-CTLA-4 and Anti-PD-1
@en
P2093
Jeffrey C Flynn
Yi-Chi M Kong
P2860
P356
10.3389/FIMMU.2014.00206
P577
2014-05-16T00:00:00Z